ABBV vs KO Comparison: AI Score, Valuation, Performance and Upside
ABBV holds the edge across 4 of 5 key metrics in this comparison. ABBV leads on both 1-year return (+24.13%) and forward P/E (13.32x vs 22.79x for KO), a relatively favorable combination of momentum and valuation. On fundamentals, ABBV is growing revenue faster (12.40%), while KO maintains the higher operating margin (35.05%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for ABBV (+17.12%) than for KO (+8.29%).
| Metric | ABBV | KO |
|---|---|---|
| AI score | 51.3 | 40.9 |
| AI rank | #345 | #936 |
| Latest close | $230.01 | $79.53 |
| 1M return | +6.63% | -2.39% |
| 6M return | +1.41% | +13.52% |
| 1Y return | +24.13% | +15.53% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABBV | KO |
|---|---|---|
| 1Y ago | $12.52K (+25.2%) started 2025-06-23 | $11.4K (+14.0%) started 2025-06-23 |
| 5Y ago | $27.88K (+178.8%) started 2021-06-23 | $18.53K (+85.3%) started 2021-06-23 |
| 10Y ago | $86.86K (+768.6%) started 2016-06-23 | $31.99K (+219.9%) started 2016-06-23 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABBV | KO |
|---|---|---|
| Market cap | $382.49B | $341.57B |
| Trailing P/E | 106.12 | 24.97 |
| Forward P/E | 13.32 | 22.79 |
| Price/Sales | 5.85 | 6.55 |
| EV/Revenue | 7.10 | 7.60 |
| Analyst target | $253.55 | $85.97 |
| Target upside | +17.12% | +8.29% |
| Metric | ABBV | KO |
|---|---|---|
| Revenue growth | 12.40% | 12.10% |
| Earnings growth | -46.20% | 18.20% |
| EPS growth | -46.20% | +18.20% |
| FCF margin | +33.13% | +6.34% |
| Operating margin | 32.16% | 35.05% |
| Profit margin | 5.79% | 27.80% |
| ROIC proxy | 6225.00% | 43.37% |
| Return on equity | 6225.00% | 43.37% |
| Dividend yield | 3.20% | 2.67% |
| Beta | 0.31 | 0.35 |
| Debt/equity | 4789.60 | 124.94 |
| Current ratio | 0.80 | 1.36 |
| Quick ratio | 0.52 | 0.78 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABBV | KO |
|---|---|---|---|
| 1Y | Growth | +25.17% | +14.04% |
| CAGR | +25.27% | +14.09% | |
| Sharpe ratio | 0.84 | 0.60 | |
| Max drawdown | 19.23% | 8.50% | |
| Max daily drop | 5.20% | 2.58% | |
| Max wkly drop | 8.49% | 5.54% | |
| 5Y | Growth | +135.70% | +64.51% |
| CAGR | +18.71% | +10.47% | |
| Sharpe ratio | 0.67 | 0.42 | |
| Max drawdown | 21.92% | 17.27% | |
| Max daily drop | 12.57% | 6.96% | |
| Max wkly drop | 17.30% | 7.43% | |
| 10Y | Growth | +448.60% | +132.77% |
| CAGR | +18.56% | +8.82% | |
| Sharpe ratio | 0.62 | 0.31 | |
| Max drawdown | 45.09% | 36.99% | |
| Max daily drop | 16.25% | 9.67% | |
| Max wkly drop | 19.39% | 20.98% |
| Category | ABBV | KO |
|---|---|---|
| Company | ABBV | KO |
| Sector | Healthcare | Consumer Defensive |
| Industry | Drug Manufacturers - General | Beverages - Non-Alcoholic |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.